KURVE THERAPEUTICS, INC., A DELAWARE CORPORATION COMMON STOCK SHARES REGULATION A+ SUBSCRIPTION AGREEMENTRegulation A+ Subscription Agreement • September 29th, 2022 • Kurve Therapeutics, Inc. • Pharmaceutical preparations
Contract Type FiledSeptember 29th, 2022 Company IndustryInvesting in securities represented by shares of common stock (“Shares”) of Kurve Therapeutics, Inc. (the “Company”) involves significant risks. This investment is suitable only for persons who can afford to lose their entire investment and such investment could be illiquid for an indefinite period of time. No public market currently exists for the Shares, and if a public market develops following this offering, it may not continue.
MCGINLEY ORTHOPAEDIC INNOVATIONS, INC., A WYOMING CORPORATION COMMON STOCK SHARES REGULATION A+ SUBSCRIPTION AGREEMENTRegulation A+ Subscription Agreement • August 11th, 2022 • McGinley Orthopaedic Innovations, Inc.
Contract Type FiledAugust 11th, 2022 CompanyInvesting in securities represented by shares of common stock (“Shares”) of McGinley Orthopaedic Innovations, Inc. (the “Company”) involves significant risks. This investment is suitable only for persons who can afford to lose their entire investment and such investment could be illiquid for an indefinite period of time. No public market currently exists for the Shares, and if a public market develops following this offering, it may not continue.
FACIBLE BIODIAGNOSTICS, INC., A DELAWARE CORPORATION CLASS A COMMON STOCK SHARES REGULATION A+ SUBSCRIPTION AGREEMENTRegulation A+ Subscription Agreement • May 9th, 2022 • Facible BioDiagnostics, Inc.
Contract Type FiledMay 9th, 2022 CompanyInvesting in securities represented by shares of Class A common stock (“Shares”) of Facible BioDiagnostics, Inc. (the “Company”) involves significant risks. This investment is suitable only for persons who can afford to lose their entire investment and such investment could be illiquid for an indefinite period of time. No public market currently exists for the Shares, and if a public market develops following this offering, it may not continue.